Biotechnology group Amgen has signed a deal with UK pharmaceutical firm GlaxoSmithKline (GSK), it was announced yesterday. Thousand Oaks, California-based Amgen will team up with GSK to jointly commercialize Amgen's hotly-anticipated experimental osteoporosis drug denosumab in Europe and emerging markets. The deal marks a significant move into primary care drugs and international markets for Amgen, which is attempting to increase sales following criticism for over-pricing.